SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Scott will provide his perspective on the investment outlook for early stage companies on a panel at the Bloom Burton & Co Technology Transfer Conference May 21 in Toronto.
News | 05. 21. 2013
Scott will provide his perspective on the investment outlook for early stage companies on a panel at the Bloom Burton & Co Technology Transfer Conference May 21 in Toronto.
